FORM 4

UNITED STATES SEC

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

URITIES AND EXCHANGE COMMISS	OI	Λ	1
------------------------------	----	---	---

OMB APPROVAL										
OMB Number:	3235-028									
Estimated average	burden									

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Pulla 105.1(c). See
conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Chacko Jacob</u>					2. Issuer Name and Ticker or Trading Symbol Oric Pharmaceuticals, Inc. [ORIC]								eck all applic Directo	r 10% Ow		vner	
(Last) (First) (Middle) C/O ORIC PHARMACEUTICALS, INC. 240 E. GRAND AVE., 2ND FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 01/02/2025								below)	(give title ESIDEN	T AN	Other (spelow) ND CEO	pecify
(Street) SOUTH FRANCI	ISCO C	A state)	94080 (Zip)	4	. If Ame	endment, [Date o	of Original Fil	ed (M	/lonth/Da	y/Year)	Line	Form fi	led by One	Repo	(Check Appl rting Person One Report	
		Та	ble I - Non-D	erivati	ive Se	curities	s Ac	quired, D	ispo	osed o	f, or Be	neficially	y Owned				
Date			2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Ins	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr.				Beneficia	es For ially (D) Following (I) (rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code	, ,	Amount	(A) or (D)	Price	Transacti (Instr. 3 a	on(s)			(111501.4)		
			Table II - De					uired, Dis s, options	•	,		•	Owned				
Derivative Conversion Date		cise (Month/Day/Year) if any (Month/Day/Year) ive		Code	action (Instr.	5. Number Derivative Securities Acquired or Dispos of (D) (In 3, 4 and	e s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and of Securiti Underlying Derivative (Instr. 3 and	es g Security	8. Price of Derivative Security (Instr. 5)	derivativ Securitic Benefici Owned Followin Reporte	ve es ially ng	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownershi (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Exp Dat	piration te	Title	Amount or Number of Shares		Transacti (Instr. 4)	on(s)		
Stock Option (right to buy)	\$8.26	01/02/2025		A		600,000		(1)	01/0	01/2035	Common Stock	600,000	\$0	600,00	00	D	
Restricted Stock Unit	(2)	01/02/2025		Α		100,000		(3)		(3)	Common Stock	100,000	\$0	100,00	00	D	

Explanation of Responses:

- 1. 25% of the shares subject to the option shall vest on January 2, 2026, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
- 2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.
- 3. 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

/s/ Christian Kuhlen, attorneyin-fact

01/03/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.